NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00973609,Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC),https://clinicaltrials.gov/study/NCT00973609,,COMPLETED,"Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy.

The maintenance treatment with capecitabine or 5-FU/folinic acid and bevacizumab will be compared with a maintenance treatment with bevacizumab alone or no maintenance treatment. Reinduction treatment will be done in case of progression.",NO,Colorectal Neoplasms,"DRUG: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|DRUG: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|DRUG: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab","Time to failure of maintenance and reinduction treatment strategy measured from randomization, From randomization until second progression after reinduction treatment","TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research., From enrollment until second progression after reinduction treatment",,AIO-Studien-gGmbH,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE3,853,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,AIO-KRK-0207|ML21768|EudraCT-Nr.: 2008-007974-39,2009-08,2014-12,2015-08,2009-09-09,,2015-09-01,"AIO-Studien gGmbH, Berlin, 10623, Germany",
